Lipella Pharmaceuticals Inc. LIPO
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $3.4M
- P/E
- 0.0×
Follow LIPO
Growth Flags
show if company had growth for consecutive years
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| (361.77%) | (248.35%) | (154.54%) | (198.12%) |
+8 more TTM periods Free account |
|
| (236.36%) | (186.99%) | (128.38%) | (160.49%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(368.95%) | (204.55%) | (126.51%) | (267.84%) | |
Average Days of Receivables |
— | 32.60 | 60.10 | 57.64 | |
Free Cash Flow per Share |
(1.05) | (1.05) | (1.94) | (3.77) | |
Free Cash Flow |
(4.78) | (4.50) | (3.99) | (3.95) | |
Piotroski F-Score |
— | 2.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(142.84%) | (81.52%) | (48.03%) | (96.26%) | |
Accounts Receivable Turnover |
— | 12.17 | 6.73 | 9.17 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 828.18% | 724.00% | 673.60% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 461.74% | 374.40% | 373.55% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 176.99% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.90 | 0.82 | 0.78 | 0.79 | |
Depreciation/Fixed assets |
0.38 | 0.35 | 0.32 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.11 | 0.25 | 0.51 | |
Operating CF per Share |
(1.05) | (1.05) | (1.94) | (3.77) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | (1,174.03%) | (986.90%) | (935.16%) |
Columns are period end dates